Difference between revisions of "Octreotide (Sandostatin)"
m |
m |
||
| Line 17: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*1988-10-21: Initial approval for treatment of chronic and severe diarrhea and flushing episodes associated with [[Neuroendocrine tumor|carcinoid tumors]] and vasoactive intestinal peptide-secreting tumors (VIPomas). ''(No supporting studies are cited)'' | *1988-10-21: Initial approval for treatment of chronic and severe diarrhea and flushing episodes associated with [[Neuroendocrine tumor|carcinoid tumors]] and vasoactive intestinal peptide-secreting tumors (VIPomas). ''(No supporting studies are cited)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1995-06-23: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' SMS 201-995 | *'''Code name:''' SMS 201-995 | ||
| Line 37: | Line 38: | ||
[[Category:FDA approved in 1988]] | [[Category:FDA approved in 1988]] | ||
| + | [[Category:EMA approved in 1995]] | ||
Revision as of 02:02, 14 June 2023
General information
Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Octreotide (Sandostatin) patient drug information (Chemocare)[4]
- Octreotide (Sandostatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1988-10-21: Initial approval for treatment of chronic and severe diarrhea and flushing episodes associated with carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). (No supporting studies are cited)
History of changes in EMA indication
- 1995-06-23: EURD
Also known as
- Code name: SMS 201-995
- Generic names: octreotide immediate release, octreotide IR, octreotide acetate
- Brand names: Longastatina, Octrestatin, Octride, Okeron, Proclose, Samilstin, Sandostatin, Sandostatina, Sandostatine